ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Dec 01, 2022 20:09 JST
Source:
Eisai
Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium
TOKYO, Dec 01, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN, "eribulin") will be presented during the 2022 San Antonio Breast Cancer Symposium (SABCS), which is taking place virtually and in-person in San Antonio, Texas from December 6-10.
Eisai will present five eribulin-related abstracts, including a post hoc subgroup analysis from two pivotal Phase 3 studies (EMBRACE and Study 301), as well as:
- Real world use of eribulin following treatment with a P13K inhibitor, mostly in people with Hormone Receptor (HR)-positive/HER2-negative metastatic breast cancer.
- Preclinical data exploring a liposomal formulation of eribulin, in a Phase 1 expansion cohort for breast cancer, versus eribulin at the same dose, in patient-derived breast cancer xenografts.
"We continue to relentlessly pursue research that provides useful insights for people living with breast cancer," said Dr. Takashi Owa, Chief Scientific Officer, Senior Vice President, Eisai Co., Ltd. "A big part of this commitment is the ongoing sharing of our preclinical and clinical data with eribulin."
This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
For more information, visit www.eisai.com/news/2022/news202286.html.
Source: Eisai
Sectors: BioTech
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Hitachi Collaborates with NVIDIA to Accelerate Digital Transformation with Generative AI
Mar 19, 2024 19:11 JST
Mitsubishi Corporation and 7 large international companies join forces to sponsor the creation of a global e-NG coalition
Mar 19, 2024 16:40 JST
Mazda: Permanent Pride of Hiroshima Exhibition Opens April 27
Mar 19, 2024 16:02 JST
TMF Collaborates with the Okinawa Prefectural Police Headquarters to Develop Accident Prevention Approaches Integrating Police Accident Data with Vehicle Data
Mar 19, 2024 12:49 JST
Hitachi Vantara Announces Collaboration with NVIDIA to Create New Portfolio of Industrial AI Solutions
Mar 19, 2024 12:35 JST
Fujitsu Limited announces recruitment plans
Mar 19, 2024 10:34 JST
Nissan and Mitsubishi Corporation agree to explore new business in next-generation-mobility and energy-related services utilizing EVs
Mar 18, 2024 17:29 JST
Fujitsu and AWS will launch a new Modernization Acceleration Joint Initiative to enable customers across industries to drive digital transformation with fast and secure legacy modernization
Mar 18, 2024 16:12 JST
Nissan and Honda to start feasibility study of strategic partnership
Mar 18, 2024 12:14 JST
Mitsubishi Power Achieves #1 Global Gas Turbine Market Share in 2023
Mar 15, 2024 18:34 JST
Mitsubishi Corp to invest in TIER IV: Transforming regional mobility with autonomous driving
Mar 15, 2024 12:36 JST
Hitachi High-Tech Launches High-sensitivity and High-throughput Wafer Surface Inspection System LS9300AD for Wafer Manufacturers
Mar 15, 2024 11:21 JST
Japanese joint research group win Prime Minister's Award with ultra high-performance computing platform using jointly developed 64-qubit quantum computer
Mar 15, 2024 10:19 JST
MHI Establishes GX Solutions Business Domain to Promote Energy Transition Business Growth Strategy
Mar 14, 2024 13:30 JST
Fujitsu and Tokai National Higher Education and Research System collaborate on AI-based space weather research
Mar 14, 2024 10:21 JST
Mitsubishi Corporation, Mitsubishi Fuso Truck and Bus, and Mitsubishi Motors will jointly establish a new company to run an online platform providing comprehensive EV related services
Mar 13, 2024 18:06 JST
MHI Selected as Licensor of CO2 Capture Technology for Leading Low Carbon Hydrogen Production Project in Cheshire, UK
Mar 13, 2024 11:30 JST
GMO Research Activity Support & Technology launches brain MRI analysis tool developed on world class supercomputer Fugaku with Fujitsu Computing as a Service (CaaS)
Mar 12, 2024 10:20 JST
TANAKA Establishes Bonding Technology for High-Density Semiconductor Mounting Using AuRoFUSE(TM) Preforms
Mar 12, 2024 03:00 JST
Hitachi Forges a Three Year Strategic Alliance with AWS to Advance Hybrid Cloud Solutions
Mar 11, 2024 16:44 JST
More Latest Release >>
Related Release
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
3/6/2024 5:47:00 PM JST
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050
2/21/2024 3:26:00 PM JST
Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
2/20/2024 9:35:00 AM JST
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan
2/16/2024 9:31:00 AM JST
Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa
2/1/2024 6:04:00 PM JST
Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis
1/26/2024 4:26:00 PM JST
Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan
1/18/2024 3:12:00 PM JST
Eisai Listed as a Global 100 Most Sustainable Corporation for the Eighth Time
1/17/2024 5:08:00 PM JST
Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024
1/16/2024 10:25:00 AM JST
Eisai: The Scientific Advisory Group (SAG) to Convene to Discuss the Marketing Authorization Application for lecanemab in the EU
1/11/2024 4:33:00 PM JST
More Press release >>